User profiles for Paul Coplan

Paul Coplan

Vice President and Head, Medical Device Epidemiology & RWD Sciences, Johnson and …
Verified email at wharton.upenn.edu
Cited by 6111

[HTML][HTML] Hepatitis B vaccination and the risk of multiple sclerosis

…, MA Hernán, MJ Olek, PM Coplan… - … England Journal of …, 2001 - Mass Medical Soc
Background Reports of multiple sclerosis developing after hepatitis B vaccination have led
to the concern that this vaccine might be a cause of multiple sclerosis in previously healthy …

[HTML][HTML] Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory

PM Coplan, K Schmader, A Nikas, ISF Chan, P Choo… - The Journal of …, 2004 - Elsevier
In preparation for clinical trials of a vaccine against herpes zoster (HZ), we conducted a
prospective, observational study to evaluate (1) the Zoster Brief Pain Inventory (ZBPI), an HZ-…

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit–risk balance of medicines

PM Coplan, RA Noel, BS Levitan… - Clinical …, 2011 - Wiley Online Library
The current process of benefit–risk assessment of medicines relies primarily on intuitive
expert judgment. Frameworks are needed for transparent, rational and defensible decision …

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended‐release oxycodone with abuse‐deterrent …

PM Coplan, H Kale, L Sandstrom… - … and drug safety, 2013 - Wiley Online Library
Purpose Abuse and misuse of prescription opioids are serious public health problems.
Abuse‐deterrent formulations are an intervention to balance risk mitigation with appropriate …

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and …

…, ND Wolfe, M Aste-Amezaga, DR Casimiro, P Coplan… - Vaccine, 2010 - Elsevier
Replication-defective adenoviruses have been utilized as candidate HIV vaccine vectors.
Few studies have described the international epidemiology of pre-existing immunity to …

[HTML][HTML] Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals …

…, RA Black, C Landau, SH Budman, PM Coplan - The Journal of …, 2013 - Elsevier
Oxycodone hydrochloride controlled-release, also known as extended-release oxycodone (ER
oxycodone), was reformulated with physicochemical barriers to crushing and dissolving …

The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults

…, R Sloane, C Pieper, PM Coplan… - The Clinical journal …, 2007 - journals.lww.com
Objectives To describe the interference of herpes zoster (HZ) pain and discomfort with
activities of daily living (ADLs) and health-related quality of life (HRQL) during the acute rash …

Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study

…, TN Tran, S Black, HR Shinefield, PM Coplan… - …, 2013 - publications.aap.org
BACKGROUND: Varicella vaccine was licensed in the United States in 1995 for individuals
≥12 months of age. A second dose was recommended in the United States in June 2006. …

Perceptions of sexual behavior and knowledge about sexually transmitted diseases among adolescents in Benin City, Nigeria

…, FO Omorodion, EP Renne, P Coplan… - International family …, 1999 - JSTOR
Context: The level of sexual activity and the incidence of sexually transmitted diseases (STDs)
are high among Nigerian adolescents, but use of reproductive health services is low. …

[HTML][HTML] Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010

…, A Muñoz, MF Schneider, H Chilcoat, PM Coplan… - The journal of pain, 2013 - Elsevier
This study evaluated changes in abuse exposures, therapeutic error exposures, and diversion
into illegal markets associated with brand extended-release oxycodone (ERO) following …